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Resistance to chemotherapy is a hallmark of pancreatic ductal adenocarcinoma (PDA) and has been partly
attributed to the dense desmoplastic stroma, which forms a protective niche for cancer cells. Tissue
transglutaminase (TG2), a Ca2+-dependent enzyme, is secreted by PDA cells and cross-links proteins in the
tumor microenvironment (TME) through acyl-transfer between glutamine and lysine residues, promoting PDA
growth. The objective of the current study was to determine whether secreted TG2 by PDA cells alters the
response of pancreatic tumors to gemcitabine. Orthotopic pancreatic xenografts and co-culture of PDA and
stromal cells were employed to determine the mechanisms by which TG2 alters tumor-stroma interactions and
response to gemcitabine. Analysis of the pancreatic The Cancer Genome Atlas (TCGA) database demonstrated
that increased TG2 expression levels correlate with worse overall survival (hazard ratio = 1.37). Stable TG2
knockdown in PDA cells led to decreased size of pancreatic xenografts and increased sensitivity to gemcitabine in
vivo. However, TG2 downregulation did not increase cytotoxicity of gemcitabine in vitro. Additionally, multivessel
density and gemcitabine uptake in pancreatic tumor tissue, as measured by mass spectrometry (MS-HPLC), were
not significantly different in tumors expressing TG2 versus tumors in which TG2 was knocked down. Fibroblasts,
stimulated by TG2 secreted by PDA cells, secrete laminin A1, which protects cancer cells from gemcitabine-
induced cytotoxicity. In all, our results demonstrate that TG2 secreted in the pancreatic TME orchestrates the
cross talk between cancer cells and stroma, impacting tumor growth and response to chemotherapy. Our study
supports TG2 inhibition to increase the antitumor effects of gemcitabine in PDA.
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Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause
of cancer mortality in the world [1]. PDA metastasizes early and is
resistant to currently available therapy [2,3]. A hallmark of pancreatic
cancer is the dense desmoplastic stroma composed of activated
myofibroblasts, pancreatic stellate cells, collagen, and other extracel-
lular matrix (ECM) proteins [4–6]. Tissue transglutaminase (TG2), a
calcium (Ca2+)-dependent enzyme that catalyzes protein transamida-
tion through acyl-transfer between glutamine and lysine residues, is
abundantly expressed in pancreatic cancer cells and secreted in the
pancreatic stroma. We recently showed that TG2 contributes to
pancreatic cancer progression by modulating the tumor microenvi-
ronment (TME) through collagen cross-linking, which in turn
stimulates proliferation and activation of fibroblasts [7]. This
fibroblast and TG2-mediated cross-linked collagen- rich stroma in
turn stimulates tumor growth by activating the Yes-associated protein
and transcriptional co-activator with PDZ-binding motif oncogenic
signaling. Here, we set out to determine whether stroma modifica-
tions induced by TG2 also alter the response of pancreatic tumors to
chemotherapy.
Previous reports have shown that TG2 overexpression in pancreatic
tumors is associated with poor clinical outcomes and resistance to
chemotherapy [3,8]. Resistance to anticancer agents is generally
attributed to intra- or extracellular cellular mechanisms. Intracellular
mechanisms of resistance in PDA include overexpression of the
P-glycoprotein and of other transporters [9,10] or activation of
antiapoptotic proteins, such as Bcl-xL and NF-κB [11,12]. Previous
studies attributed TG2-induced resistance to gemcitabine to
activation of the NF-κB survival signaling and of the focal adhesion
kinase/phosphatidylinositol 3-kinase/AKT signaling pathways [3,8].
Extracellular mechanisms of resistance involve interactions between
tumor cells and the surrounding stroma, which provide cancer cells
with powerful survival cues protecting them from chemotherapy- or
radiation-induced apoptosis [13,14]. Recent reports have suggested
that inefficient drug delivery within the pancreatic milieu due to the
dense stroma contributes to resistance to chemotherapy [15]. Here,
we examined how the interplay between cancer and stromal cells
mediated by TG2 secreted within the TME contributes to resistance
to gemcitabine.
TG2 is a multifunctional protein, whose roles are regulated by
subcellular localization and environmental factors, Ca2+ andGTP being
the two key regulators [16–18]. TG2 binding of Ca2+, typically in the
ECM, causes an extended (open) conformation exposing the catalytic
core, which promotes the enzymatic activity and inhibits the binding
and hydrolysis of GTP. On the contrary, TG2 binding of GTP in the
intracellular space induces a compact (closed) conformation and
inhibits the catalytic activity [19]. In the cytoplasm where Ca2+
concentration is low, the transamidating activity is inhibited [18,20],
whereas in the extracellular compartment, where Ca2+ concentration is
high, TG2 is enzymatically active and modifies extracellular proteins by
cross-linking [21]. Here, we focused on the functions of TG2 in the
ECM of pancreatic tumors.
By using co-culture system and pancreatic orthotopic xenografts, we
demonstrate that TG2 knockdown in PDA cells inhibited response to
gemcitabine in vivo but not in vitro. This discrepancy suggests that its
effects occurred primarily through modulation of the TME. The
co-culture of PDA cells with fibroblasts stimulated cancer cell
proliferation, and TG2-mediated cross-linked collagen stimulated the
proliferation of cancer-associated myofibroblasts. Cancer-associatedfibroblasts co-cultured with cancer cells in which TG2 was knocked
down secrete decreased levels of laminin 1, which in turn partly
protected PDA cells from gemcitabine-induced cytotoxicity. Collec-
tively, our data support that TG2 facilitates the cross talk between
cancer and stromal cells, therebymodulating response to chemotherapy.
Materials and Methods
Chemicals and Reagents
Antibodies for TG2 (NeoMarkers, Fremont, CA; #CUB7402) and
GAPDH (Meridian Life Science, Inc., Memphis, TN) were used for
Western blotting at dilutions of 1:1000 and 1:20,000, respectively.
Antibodies for TG2 (NeoMarkers; #RB-060-P1ABX), Laminin 1,
Ki67, and CD31 (Abcam, Cambridge, MA) were used for
immunohistochemistry (IHC) at a dilution of 1:50 and or 1:100.
Cell Culture
AsPC1 and BxPC3 cells were purchased from the American Type
Culture Collection (Rockville, MD), Panc1 and MIA PaCa-2 (Paca2)
cells were a gift from Prof. Murray Korc (Indiana University Melvin
and Bren Simon Cancer Center [IUSCC], Indianapolis, IN), and
green fluorescence protein (GFP) expressing AsPC1 (GFP-AsPC1)
cells were provided by Dr. Jingwu Xie (IUSCC, Indianapolis, IN).
Human pancreatic stellate cells (hPSCs) were obtained from
ScienCell Research Laboratories (Carlsbad, CA), GFP-expressing
human neonatal dermal fibroblasts (GFP-HNDFs) were purchased
from Angioproteome (Boston, MA), and normal human dermal
fibroblasts (NHF544) were provided by Dr. Dan Spandau (IUSCC,
Indianapolis, IN). Human pancreatic cancer-associated fibroblasts
(CAFs; UH1303-35) were isolated from a human pancreatic tumor
by using the outgrowth method and immortalized by transduction of
telomerase (hTERT). AsPC1, GFP-AsPC1, and BxPC3 cells were
cultured in RPMI 1640 medium (Cellgro, Manassas, VA) supple-
mented with 10% fetal bovine serum and 1% antibiotics. Panc1,
Paca2, hPSCs, GFP-HNDFs, NHF544, and CAFs were grown in
Dulbecco's modified Eagle's medium (Cellgro) supplemented with
10% fetal bovine serum and 1% antibiotics. Cells were grown at 37°C
under 5% CO2. Conditioned medium was collected after 24-hour
incubation of 5 × 105 PDA cells in 1 ml of serum-free RPMI
medium. Debris was removed by centrifugation at 1200 rpm for 5
minutes. Laminin (Sigma-Aldrich, St. Louis, MO) diluted with sterile
Hank's balanced salt solution (HBSS) was used to coat 96-well plates
at 5 to 10 μg/cm2 for 2 hours at 37°C. PDA cells were plated on this
matrix at a density of 2.5 × 103 to 2 × 104 cells per well for 16 hours
(O/N). Gemcitabine (Eli Lilly, Indianapolis, IN) treatment was
applied at the indicated concentrations.
Co-Culture
For indirect co-culture, 3.5 × 105 hPSCs were cultured in the CM
collected from PDA cells for 48 hours. RNA isolated from the hPSCs
was used for gene expression analysis employing the RT2 Profiler
PCR Array. For direct co-culture, 5 × 103 GFP-AsPC1 cells and 5 ×
103 NHF544 were mixed and co-cultured in a 96-well plate for 96
hours. In addition, 1.5 × 104 GFP-AsPC1 cells and 1.5 × 104 CAFs
were mixed and co-cultured in 24-well plates for 48 hours.
Proliferation Assays
Cell counting kit (CCK)-8 (Dojindo Molecular Technologies,
Inc., Rockville, MD) was used to determine the proliferation of PDA
cells and CAFs according to the manufacturer's instructions.
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reader (BioTek Instruments, Inc., Winooski, VT). The CCK-8 cell
counting kit or the bromodeoxyuridine cell proliferation
enzyme-linked immunosorbent assay kit (Abcam) was used to
measure proliferation of PDA cells cultured on laminin. Absorbance
at 370 nm (reference wavelength, 492 nm) was measured by
SPECTRAmax Plus 384 microplate spectrophotometer (Molecular
Devices, Sunnyvale, CA). Proliferation of GFP-AsPC1 cells in a direct
co-culture with NHF544 was measured every 24 hours for 96 hours
by assessing fluorescence intensity (relative fluorescence units) using
the SpectraMax Gemini XS microplate fluorometer (Molecular
Devices) at 485-nm excitation and 538-nm emission. LUNA-FL
Automated Fluorescence Cell Counter (Logos Biosystems, Inc.,
Annandale, VA) was used to assess the alive GFP-AsPC1 cells in a
direct co-culture with CAFs after 48 hours of gemcitabine treatment
by counting the number of GFP-expressing cells. The assays were
repeated three times.
Cell Transfection
TG2 was stably knocked down in AsPC1 and BxPC3 cells by
transducing MISSION shRNA Lentiviral Transduction Particles
(Sigma-Aldrich) as previously described [7]. Briefly, the PDA cells
were transduced with scrambled shRNA (shCtrl) or shTG2, followed
by polyclonal selection with puromycin (1 μg/ml). TG2 knockdown
was confirmed by Western blotting.
Western Blotting
Cells were lysed in radioimmunoprecipitation assay buffer containing
Halt protease inhibitor cocktail (Thermo Scientific, Waltham, MA).
Equal amounts of proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transferred to polyvinylidene
difluoride membranes (Bio-Rad Laboratories, Inc., Hercules, CA).
After blocking, membranes were blotted with primary antibodies
followed by HRP-conjugated secondary antibodies. The
protein-antibody complexes were visualized by enhanced chemilumi-
nescence solution (Thermo Fisher Scientific), and images were captured
by ImageQuant LAS 4000 mini imager with a Chemilux CCD camera
(GEHealthcare, Uppsala, Sweden). The shRNA effects were quantified
by densitometry by using ImageJ software. All analyses were repeated at
least three times.
Orthotopic Pancreatic Xenograft Mouse Model
Animal experiments were conducted after review and approval by the
IU Animal Care and Use Committee and were in compliance with
federal regulations. Briefly, 1.5 × 105 AsPC1 cells, stably transduced
with shRNA targeting TG2 or scrambled shRNA (shCtrl; control),
diluted in 50 μl of medium were injected into the tail of pancreas of 7-
to 8-week-old female nude mice (nu/nu Balbc) from Harlan
(Indianapolis, IN) using a 27.5-gauge needle under isoflurane
anesthesia, as previously described [7]. Gemcitabine at a concentration
of 25 mg/kg or PBS (control) was administered to tumor-bearing mice
(n = 7 per PBS group and n = 8 per gemcitabine group) twice a week
for 4 weeks via intraperitoneal injection. Mice were euthanized after 4
weeks, and tumor weights, volumes, and numbers of metastases were
assessed. Tumors were measured three-dimensionally, and tumor
volumes were calculated as 4/3*π*(L/2)*(W/2)*(H/2), where L is
length,W is width, andH is height. Metastatic implants were counted.
To determine gemcitabine distribution in tissue, gemcitabine was
administered as a single dose (25 mg/kg) via intravenous (iv) injectionto tumor-bearing mice 4 weeks after PDA cell implantation (shCtrl;
n = 5, shTG2; n = 6). Mice were euthanized 2 minutes after
gemcitabine administration [22], and tumors and plasma were
immediately collected and processed.
Gemcitabine Concentration Measurement
Tumors were harvested and homogenized in phosphate buffer
containing tetrahydrouridine, a cytidine deaminase inhibitor, to prevent
the degradation of gemcitabine to 2′,2′-difluorodeoxyuridine (dFdU).
Liquid-liquid extraction, internal standardization (5-azacytidine), and
HPLC–tandemmass spectrometry was used to measure gemcitabine and
dFdU in tumor tissue and plasma. Tumor homogenates in
tetrahydrouridine-containing phosphate buffer were extracted with
ethyl acetate, the extract was transferred to a different tube, and the
ethyl acetate was evaporated to dryness. Mobile phase was added to each
tube, an aliquot was injected into the HPLC, and the compounds were
separated using a C8 column (5 μm; 4.6 × 250 mm Zorbax).
Compounds were detected by electrospray ionization tandem mass
spectrometry in positivemode (ThermoQuantumUltra; ThermoFisher)
using 264/112, 265/113, and 245/113 as the Q1/Q3 for gemcitabine,
dFdU, and 5-azacytidine, respectively. The lower limit of quantification
was 1 ng/ml and 30 ng/ml for gemcitabine and dFdU, respectively.
Immunohistochemistry
Paraffin-embedded orthotopic pancreatic xenografts were deparaffi-
nized and immunostained with TG2 polyclonal (Neomarkers),
Laminin 1, Ki67, or CD31 (Abcam) antibodies after sodium citrate
antigen retrieval. Secondary labeling was based on the Avidin/Biotin
system (Dako North America, Inc.). Slides were stained with
3,3′-diaminobenzidine and counterstained with hematoxylin. Negative
controls were run in parallel, with isotype IgG control. Microvessel
density (MVD) was counted at the interface with stroma or, if no
adjacent normal tissue was present, at the edge of the tissue section.
Multiple (8 to 18) 200× fields were counted on an Olympus BX51
microscope around the entire perimeter of the largest section of tumor
present on the slide. CD31 immunoreactivity alone was not considered
sufficient for identification of a vessel, as nonspecific staining was
observed in zones of necrosis, in plasma cells, and occasionally within
the tumor cells. A vessel was counted when a CD31-positive structure
formed a lumen, had associated cells morphologically consistent with
endothelial cells, or contained erythrocytes. Percentages of
Ki67-staining cells relative to all nuclei were counted in five 100×
fields per specimen, and average counts were calculated. Slides were
reviewed and scored by a board-certified pathologist.
RT2 Profiler PCR Array
The human ExtracellularMatrix and AdhesionMolecules RT2 Profiler
PCR Array was purchased from SA Bioscience (Valencia, CA), and
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
was performed on ABI Prism 7900HT (Applied Biosystems, Foster City,
CA) according to the manufacturer's instructions.
Quantitative Real-Time PCR
Total RNA was isolated using RNA STAT-60 Reagent (Tel-Test
Inc., Friendswood, TX) and reverse-transcribed using iScript cDNA
synthesis kit (Bio-Rad Laboratories, Inc.). The primers for qRT-PCR
were: LAMA1 forward: AGG AGT GGG TGT GTG ACG A and
reverse: CCA GGC AGT TGG CTC TAA TC and GAPDH
forward: AGC CAC ATC GCT CAG ACA C and reverse: GCC
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calculated using Ct method, 2−ΔCt = 2−[Ct(CTGF) − Ct(GAPDH)], where
Ct is the cycle threshold value defined as the fractional cycle number at
which the target fluorescent signal passes a fixed threshold. All experiments
were performed in duplicates in three independent experiments, and
results are presented as means ± standard error (SE) of replicates.
Statistical Analysis
Student's t test was used to compare measurements between
groups. P values b .05 were considered significant. For the survival
analysis, mRNA expression level data (Level 3 Illumina RNASeqv2),
publicly available from TCGA (http://tcgadata.nci.nih.gov/) for 178
patients with pancreatic adenocarcinoma, were used. The clinical
information was retrieved from cbioPortal (http://www.cbioportal.
org/). The overall survival information was complete for 76 patients.
Statistical analyses were performed in R (version 3.0.1) (http://www.
r-project.org/), and the statistical significance was defined as a P value
less than .05. We performed Cox regression analysis as an initial screen
for associations between survival and TG2 mRNA expression. We
observed an association between TG2 expression and shorter
overall survival: hazard ratio (HR) = 1.37, 95% confidence interval
(CI) = 1.02-1.85, and P value (Wald test) = .0377. We then used the
log-rank test to find the point (cutoff) with the most significant (lowest
P value) split in high- and low-TG2 groups. The Kaplan-Meier plots
were generated for this cutoff (0.75) (P = .025). The numbers of
patients at risk in low-/high-TG2 groups at different time points are
presented at the bottom of the graph. The Spearman's rank-order
correlation test was applied to measure the strength of the association
between TGM2 and LAMA1.
Results
TG2 Expression and Response to Gemcitabine In Vitro
Endogenous TG2 expression levels were measured in PDA cell lines
and in fibroblasts (GFP-HNDF) by immunoblotting (Figure 1A,
upper). Among PDA cells, AsPC1 and BxPC3 cells expressed relatively
abundant TG2, whereas Panc1 and Paca2 cells expressed relatively low
TG2 levels. Fibroblasts also expressed endogenous TG2, consistent
with our previous observations demonstrating TG2 expression in
PDA-associated stroma [7]. TG2 was knocked down in AsPC1 and
BxPC3 cells by stably transducing shRNA targeting TG2 (shTG2).
TG2 expression levels were significantly decreased in cells stably
transducedwith shTG2 comparedwith cells transducedwith scrambled
shRNA (shCtrl; Figure 1A, lower).
To determine whether TG2 expression is associated with clinical
outcomes in patients with PDA, the publically available database
associated with the pancreatic cancer TCGA project was analyzed.
Tumors with high TG2 expression levels were associated with poor
survival compared with those expressing low TG2 (Figure 1B, HR =
1.37, 95% CI = 1.02-1.85, P = .0377). These data suggest that TG2
expression alters clinical outcome either by impacting tumor
progression or by altering response to treatment.
To measure the effects of TG2 on cell proliferation and response to
gemcitabine, cell proliferation was assessed in PDA cells in which
TG2 expression was knocked down by using shRNA. Interestingly,
TG2 knockdown did not alter proliferation of AsPC1 (Figure 1C) or
BxPC3 cells (Figure 1D). Likewise, TG2 knockdown did not
significantly alter the response of AsPC1 (Figure 1E) or BxPC3 cells
(Figure 1F) to gemcitabine, suggesting that the enzyme does not havea measurable impact on cell growth and sensitivity to gemcitabine
in vitro.
TG2 Expression and Response to Gemcitabine In Vivo
We next tested whether knockdown of TG2 in PDA cells induces
sensitivity to gemcitabine in vivo. For this, we used orthotopic
pancreatic xenografts derived from AsPC1 + shCtrl or + shTG2 cells.
After cell implantation, mice were treated with gemcitabine twice a
week for 4 weeks at a dose of 25 mg/kg via intraperitoneal injection
(n = 7 per PBS group and n = 8 per gemcitabine group). In
concordance with our previous data [7], average tumor volumes and
weights were significantly decreased in xenografts derived from
AsPC1 + shTG2 cells compared with controls (Figure 2A, left and
middle, P = .002 and P = .001, respectively), whereas there was no
significant difference in the number of macrometastases between the
two groups (Figure 2A, right, P = .55). Gemcitabine treatment
decreased the average tumor volume and weight in both
AsPC1 + shCtrl–and AsPC1 + shTG2–derived xenografts compared
with PBS (Figure 2A, left and middle, P b .002). Furthermore,
average tumor volume and weight were lower in AsPC1 + shTG2–
derived xenografts treated with gemcitabine compared with controls
treated with gemcitabine (Figure 2A, left and middle, P = .01 and
P = .03, respectively). In addition, gemcitabine treatment signifi-
cantly decreased number of macrometastases in mice bearing
AsPC1 + shTG2 xenografts compared with mice carrying
AsPC1 + shCtrl tumors (Figure 2A, right, P = .005). Together,
these data suggest that TG2 knockdown in vivo inhibits tumor
growth and that the combination of TG2 knockdown and
gemcitabine induces the most significant reduction in tumor burden.
Stable knockdown of TG2 in pancreatic xenografts was confirmed
by IHC, and the effect of TG2 knockdown on cell proliferation in
vivo was determined by immunostaining for Ki67 in xenografts
(Figure 2B, upper). In contrast to the in vitro results showing no effects
of TG2 knockdown on PDA cell proliferation, the number of
Ki67-positive PDA cells in AsPC1 + shTG2 xenografts was signifi-
cantly decreased compared with that of control tumors (Figure 2B,
lower, n = 3 per group, P = .042). Additionally, tumor vascularization
was assessed by counting the number of vascular structures detectable
through CD31 immunostaining in AsPC1 + shTG2 and control
xenografts. No significant MVD difference was detectable between
groups (Figure 2C, n = 6 per group, P = .2).TG2 Expression and Penetrance of Gemcitabine in Tumor
Tissues
Based on our previous findings showing decreased fibrosis in pancreatic
tumors derived fromPDAcells inwhichTG2was stably knockeddown [7],
we sought to determine whether the more pronounced gemcitabine effects
were due to increased penetrance of gemcitabine. To determine gemcitabine
concentrations in tumor tissue depending onTG2 expression levels, weused
orthotopic pancreatic xenografts derived from AsPC1 + shCtrl and +
shTG2 cells. Four weeks after PDA cell implantation, when tumors were
formed, mice were given a single iv gemcitabine dose of 25 mg/kg prior to
tumor harvest within 2minutes. The uptake of gemcitabine in the pancreas
occurs within minutes after iv administration, and gemcitabine gets rapidly
excreted [22,23]. The sum of gemcitabine and dFdU concentrations in
tumor tissues was slightly higher in the AsPC1 + shTG2 xenografts
compared with controls but did not reach statistical significance (Figure 2D,
shCtrl; n = 5 and shTG2; n = 6, P = .4). Plasma gemcitabine and dFdU
Figure 1. TG2 expression and response to gemcitabine in vitro. (A) Western blotting for TG2 and GAPDH (internal control) in PDA cells,
fibroblasts (upper), and PDA cells stably transduced with shRNA targeting TG2 (shTG2) or scrambled shRNA (shCtrl; lower). The bar
graphs represent quantification of TG2 knockdown in AsPC1 and BxPC3 cells by densitometry. (B) Kaplan-Meier survival plots of patients
with PDA according to the TG2 expression level. The numbers of patients at risk in low-/high-TG2 groups at different time points are
presented at the bottom of the graph.Relative proliferation of AsPC1 + shCtrl and + shTG2 cells (C) and BxPC3 + shCtrl and +shTG2
cells (D) at 24 and 48 hours of culture (CCK-8 assay).Dose-response curves representing percentage of surviving AsPC1 + shCtrl and +
shTG2 cells (E) and BxPC3 + shCtrl and + shTG2 cells (F) after 48 hours of gemcitabine treatment (CCK-8 assay).
Neoplasia Vol. 18, No. 11, 2016 TG2 and the Desmoplastic Pancreatic Stroma Lee et al. 693concentrations were similar between the groups (data not shown).
This nonsignificant trend could reflect the variability observed within
groups and does not completely exclude an effect of TG2 knockdown
on gemcitabine tissue penetrance. Taken altogether, our findings
demonstrate that the effects of TG2 on tumor growth and response to
gemcitabine are not due to the direct effects of TG2 on PDA cells or to
altered tumor vascularity and intratumoral drug delivery.
Effects of Gemcitabine in Co-Culture of PDA Cells with
Fibroblasts
To determine whether the effects of TG2 on tumor growth and
response to gemcitabine in vivo could be mediated by the stromal
fibroblasts, we assessed their effects on PDA cell proliferation and
response to chemotherapy. Co-culture of GFP-AsPC1 cells withNHF544 fibroblasts (ratio of 1:1) showed increased proliferation of
PDA cells grown in the presence of fibroblasts compared with AsPC1
cells cultured alone (Figure 3A, P b .05). As we have previously
shown that TG2-expressing tumors are enriched in cross-linked
collagen 1 [7], we next sought to determine whether the presence of
collagen stimulates fibroblast proliferation. For this, we used
immortalized pancreatic CAFs cultured on uncoated plates or on
plates coated with either native collagen 1 or TG2-mediated
cross-linked collagen 1. The proliferation of CAFs was increased on
collagen-coated compared with uncoated plates (Figure 3B, P = .01)
and even more on TG2-mediated cross-linked collagen compared
with native collagen (Figure 3C, P b .001). Next, a co-culture
experiment determined the effects of fibroblasts on PDA cell response
to increasing doses of gemcitabine. The number of surviving
Figure 2. TG2 expression and response to gemcitabine in vivo. (A) Average tumor volumes (left), weights (middle), and numbers of metastases
(right) of xenografts derived from AsPC1 + shCtrl and + shTG2 cells and treated with gemcitabine (n = 8) or PBS (n = 7). Bars represent
average measurements ± SE. *P b .05. (B) IHC for TG2 and Ki67 (upper) and a graph representing relative percentage of Ki67-positive cells
(lower, n = 3per group,P = .042) in AsPC1 + shCtrl and+shTG2 xenografts. Ki67-positive cellswere counted in five fields per sample. (C) IHC
for CD31 (upper) and a graph representing average number of vessels counted (lower) in AsPC1 + shCtrl and + shTG2 xenografts (n = 6 per
group, P = .2). Bars represent average vessel counts ± SE. (D) Sum of gemcitabine and dFdU concentration per tumor weight (ng/g) in
AsPC1 + shCtrl and + shTG2 xenografts (shCtrl; n = 5 and shTG2; n = 6, P = .4). Bars represent average concentrations ± SE.
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gemcitabine treatment compared with those cultured in the presence
of fibroblasts (Figure 3D, P b .05), supporting a protective effect of
stromal cells against gemcitabine.
Effects of Laminin A1 Secreted by Stromal Cells on
Gemcitabine-Induced Cytotoxicity
To determine the mechanism by which TG2 secreted by PDA cells
modifies fibroblasts to induce a protective tumor environment, a
qRT-PCR array was used to compare mRNA expression levels ofstroma-associated genes in hPSCs cultured with CM from AsPC1
cells stably transduced with shRNA targeting TG2 or controls
(Figure 4A). Of 84 genes measurable in the array, 4 transcripts were
downregulated more than twofold in hPSCs indirectly co-cultured
with AsPC1 + shTG2 cells compared with control AsPC1 cells.
These transcripts include laminin A1 (LAMA1), collagen 12A1,
MMP12, and NCAM1 (Figure 4B). Decreased mRNA expression of
LAMA1 was confirmed by qRT-PCR in hPSCs co-cultured with
CM from AsPC1 + shTG2 cells compared with that from
AsPC1 + shCtrl cells (Figure 4C, P b .05) and in AsPC1 + shTG2
Figure 3. Fibroblasts modulate the response of PDA cells to gemcitabine in vitro. (A) Proliferation of GFP-AsPC1 cells in co-culture with
NHF544 or cultured alone. Green fluorescence in GFP-AsPC1 cells was measured at 485-nm excitation and 538-nm emission. Bars
represent average relative fluorescence units of triplicates ± SE. *P b .05. Proliferation of CAFs (CCK-8 assay) cultured for 48 hours on
collagen-coated or uncoated plates (B, P = .01) and on native or TG2-mediated cross-linked collagen (C, P b .001). Bars represent
average measurements ± SE. (D) Relative number of alive GFP-AsPC1 cells cultured alone or with CAFs after 48 hours of gemcitabine
treatment. Bars represent average measurements ± SE. *P b .05.
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group, P b .05). Furthermore, decreased LAMA1 protein expression
level, as measured by IHC, was observed in AsPC1 + shTG2
pancreatic xenografts compared with control xenografts (Figure 4E),
confirming the association. To test whether a direct correlation
between LAMA1 and TG2 gene expression also exists in human
pancreatic tumors, the publically available TCGA database was
explored. A significant correlation between TG2 and LAMA1
expression levels was demonstrated by the Spearman's rank-order
correlation test (Figure 4F, P = .002), suggesting relevance in human
tumors.
To examine the functional effects of laminin on the growth of
PDA cells, AsPC1, BxPC3, or Panc1 cells were cultured on plates
coated with 5 μg/cm2 of laminin or on uncoated plates. After 48
hours of culture, no significant difference was observed among
AsPC1, BxPC3, and Panc1 cells grown on laminin-coated versus
uncoated plates (Figure 4G). We next examined the effects of laminin
on proliferation of cells treated with gemcitabine. A partial protective
effect against gemcitabine-induced cytotoxicity was observed when
BxPC3 cells were grown on laminin-coated plates compared with
uncoated plates (Figure 4H). In contrast, collagen 1 or TG2-mediated
cross-linked collagen did not alter the response of PDA cells to
gemcitabine (Supplementary Figure 1). Collectively, our data support
that TG2 secreted by PDA cells promote fibroblast proliferation andsecretion of specific stromal factors, such as LAMA1, which in turn
contribute to the protection of cancer cells from the cytotoxic effects
of chemotherapy (Figure 5).
Discussion
Together with our previous results [7], these data support that TG2
regulates the interaction between PDA and stromal cells in pancreatic
cancer, altering tumor progression and response to gemcitabine.
Here, we show that the combination of TG2 knockdown and
gemcitabine decreased tumor volumes and number of metastases in
PDA xenografts. Given that the effects of TG2 knockdown on
responsiveness to gemcitabine were not detectable in vitro, we
speculated that the in vivo effects were mediated through
PDA-associated desmoplasia.
Indeed, we have previously shown that TG2 secreted by PDA cells
activates fibroblasts and stimulates their proliferation [7]. We
demonstrated that one of the mechanisms through which TG2
promoted the growth of fibroblasts occurred by collagen cross-linking
in the stroma [7]. Other groups have also shown that activation and
proliferation of stellate cells in the pancreatic milieu contribute to the
growth and invasiveness of pancreatic tumors [24,25]. Here we
demonstrate that TG2 knockdown in PDA cells also causes decreased
laminin secretion from fibroblasts, which contribute to increased
sensitivity to gemcitabine. Laminin is a key component of the
Figure 4. Cross-talk between PDA and stromal cells mediated by TG2. (A) Schematic of the indirect co-culture experiment. hPSCs were
cultured with CM collected from AsPC1 + shCtrl and + shTG2 cells. RNA isolated from hPSCs was used for cDNA synthesis followed by
gene expression analysis using the RT2 Profiler PCR Array. (B) List of genes differentially expressed in hPSCs cultured with
AsPC1 + shTG2 CM compared with + shCtrl CM.qRT-PCR measured LAMA1 mRNA levels in hPSCs cultured with CM from
AsPC1 + shCtrl or + shTG2 cells (C) and in xenografts derived from AsPC1 + shCtrl or + shTG2 cells (D, n = 4 per group). Bars
represent average fold changes ± standard deviation. *P b .05. (E) Representative IHC images of LAMA1 (laminin 1) in AsPC1 + shCtrl
and + shTG2 xenografts. (F) Spearman's rank-order correlation measured the correlation between TG2 and LAMA1 mRNA expression
levels in human PDA specimens from the TCGA database (P = .002). (G) Proliferation of AsPC1, BxPC3, and Panc1 cells cultured for 48
hours on laminin-coated or uncoated plates (bromodeoxyuridine assay). Bars represent average measurements ± SE. (H) Relative
proliferation of BxPC3 cells cultured on laminin-coated or uncoated plates and treated with gemcitabine for 96 hours (CCK8 assay). Bars
represent average measurements ± SE. *P b .05.
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Figure 5. Model illustrating the proposed interactions between
tumor and stroma cells mediated by TG2 in PDA.
Neoplasia Vol. 18, No. 11, 2016 TG2 and the Desmoplastic Pancreatic Stroma Lee et al. 697pancreatic ECM, and PDA cell adhesion to laminin [26,27] with
subsequent activation of signaling pathways, particularly through
activation of focal adhesion kinase, has been implicated in resistance
to chemotherapy [3,26].
Our findings are consistent with a previous report by Verma et al.
demonstrating that siRNA-mediated knockdown of TG2 inhibited
pancreatic tumor growth and enhanced gemcitabine therapeutic efficacy
[28]. By delivering gemcitabine alone or in combination with TG2-specific
siRNA-DOPC (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine) liposomes
to pancreatic tumors–bearing mice, Verma et al. demonstrated that
knockdown of TG2 significantly sensitized tumors to chemotherapy,
decreased tumor growth, and inhibited metastasis. In addition, TG2
inhibition by liposomes carrying siRNA targeting TG2 reduced cell
proliferation, angiogenesis, and phosphorylation of AKT. Our findings
differ from the previous report, as we did not observe inhibition of
metastasis or changes in tumorMVD induced by TG2 knockdown. These
differences may be related to the different approaches to TG2
downregulation in the two studies, as the liposomal delivery of siRNA in
the peritoneal cavity could have contributed to nonspecific targeting of
TG2 expression in nontumor tissue, such as the stroma and endothelial
cells. These effects of the TG2-targeting siRNA-DOPC could account for
the antiangiogenic effects observed and the subsequent inhibition of cell
proliferation, tumor growth, and metastasis. Consistent with the lack of
effect on tumor vasculature, we observed that the uptake of gemcitabine in
pancreatic tissue after iv administration was not significantly different in
AsPC1 + shTG2 xenografts compared with controls. Although a trend
toward increased gemcitabine concentrations in tumor tissue derived from
PDA cells in which TG2 was knocked down was noted, this did not reach
statistical significance perhaps due to the small number of tumors analyzed
and to the rapid degradation of the chemotherapeutic agent in vivo.
As our results are based on observations of the effects of
shRNA-mediated TG2 downregulation in PDA cells, we cannot
differentiate between the specific functions of the protein contributing
to response to chemotherapy in the pancreatic TME. Our previous
work demonstrated that TG2 is enzymatically active in the pancreatic
TME and pointed to its cross-linking activity as an important regulator
of tumor progression [7]. Based on those results, we inferred that the
enzymatic activity may be implicated in the response to chemotherapy.
However, in the absence of experiments using potent TG2 enzymaticinhibitors active in vivo, our conclusions regarding the involvement of
the catalytic activity of TG2 in the response to gemcitabine remain
limited, and additional studies should be undertaken.
Differing from previous reports [29], our study did not show that
TG2 knockdown sensitizes PDA cells to chemotherapy in vitro. A
link between TG2 and chemoresistance was well established in breast
cancer cells and attributed to activation of the NF-κB and AKT
survival signaling pathways [28–30]. Mann et al. demonstrated that
TG2 forms a complex with the regulatory protein IκBα causing its
cross-linking [8]. In pancreatic cancer cells, the cross-linked IκBα
dissociates from the Rel homology domain of NF-κB and is processed
for proteasomal degradation, resulting in nuclear localization and
constitutive activation of NF-κB. Additionally, TG2 was shown to
directly interact with the phosphatase PTEN, causing inhibition of its
phosphorylation at Ser380, ubiquitination, and proteasomal degrada-
tion [29]. Collectively, TG2-induced activation of phos-
phatidylinositol 3-kinase/AKT and NF-κB survival signaling
pathways is linked to resistance to chemotherapy and to the worse
clinical outcomes observed in patients whose tumors harbor high
levels of TG2. The analysis of the publically available pancreatic TCGA
database presented here, demonstrating an inverse correlation between
TG2 expression levels and survival of patients with PDA, is concordant
with previous studies involving patient cohorts from single institutions
[28] and supports the clinical relevance of our findings.
In all, our results demonstrate that TG2 secreted in the TME
coordinates the cross talk between PDA cells and the stroma, promoting
tumor growth and altering response to gemcitabine. This study
supports TG2 inhibition in the pancreatic stroma to increase the
antitumor effects of gemcitabine in difficult-to-treat pancreatic cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.09.003.
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